Saturday 17 October 2026 Export TRAW’s income statement to Excel — free account

Traws Pharma, Inc.

Traws Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.8 million, up 1,134.5% from fiscal 2024. In the quarter to June 2026, revenue fell 100.0%, EPS fell 1.78% and free cash flow fell 25.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.37 0.03 −7.50%

Follow TRAW

Alert me

Market cap: $6.2M
P/E: 0.0×
Fwd P/E: −0.6×
Dividend yield: —
F-score: 4/9
Altman Z: −89.55
Beneish M: 2517.31
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 1.00

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	1	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 31.54%

Capital & Financial Ratios $m

Market Cap 6.20

Revenue 2.85

Net Income (21.57)

Free Cash Flow (16.85)

Net Debt (5.02)

Current Ratio 0.93

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.62)

P/S ratio 2.06

P/B ratio 3.47

Past 5Y EPS Growth —

This Y EPS Growth (246.34%)

Next Y EPS Growth (2.92%)

Next Y revenue growth 369.53%

Next 5Y EPS Growth 56.00%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 11.57%

10-year low 10-year high

P/B against its own 10 years 75.69%

10-year low 10-year high

EV/Sales against its own 10 years 5.18%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	21	21	4	5
Receivables	0	2	4	3
Inventory	—	—	—	—
Other	—	—	—	—
	23	25	8	9

	2023	2024	2025	Q'26
Payables	6	8	6	6
ST’ Debt	—	—	—	—
Other	—	—	—	—
	9	12	11	10

Compound Annual Growth %

	10y	5y	3y
Sales	(13.17%)	64.59%	131.12%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	0	3	—	0	3
’24	0	0	0	0	0
’23	0	0	0	0	0
’22	0	0	0	0	0
’21	0	0	0	0	0
’20	0	0	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(8)	—	—	—
’25	(5)	(6)	(4)	(3)	(18)
’24	(4)	(10)	(11)	(4)	(30)
’23	(5)	(4)	(4)	(4)	(18)
’22	(4)	(4)	(4)	(4)	(16)
’21	(7)	(4)	(4)	(4)	(19)
’20	(6)	(5)	(6)	(5)	(23)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(8)	—	—	—
’25	(5)	(6)	(7)	(3)	(21)
’24	(4)	(10)	(11)	(4)	(30)
’23	(5)	(4)	(4)	(4)	(18)
’22	(4)	(4)	(4)	(4)	(16)
’21	(7)	(4)	(4)	(4)	(19)
’20	(6)	(5)	(6)	(5)	(23)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.53)	(0.16)	—	—	—
’25	2.09	(0.16)	(0.34)	(0.71)	0.82
’24	(6.00)	(121.75)	(8.81)	95.66	(107.25)
’23	(7.00)	(5.00)	(5.75)	(5.00)	(22.50)
’22	(5.00)	(4.75)	(6.50)	(6.50)	(22.75)
’21	(7.50)	(6.75)	(5.50)	(4.00)	(24.00)
’20	(11.24)	(14.99)	(11.24)	(11.24)	(52.47)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	11,868.75	6,806.25	633.75	37.50	71.25	61.25	15.50	13.75	4.06	0.97	Analyst estimates 2026–2028 Powerpack
	High	57,937.50	21,825.00	15,018.75	1,811.25	585.00	723.75	71.00	37.25	27.50	9.51
People
People	Employees	23	25	25	19	12	15	17	17	7	7
	Revenue/emp, $m	0.24	0.03	0.05	0.11	0.02	0.02	0.01	0.01	0.03	0.40
Income, $m
Income, $m	Revenue	6	1	1	2	0	0	0	0	0	3
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	(20)	(24)	(21)	(21)	(25)	(16)	(19)	(19)	(167)	9
	EBT margin, %	(354.36)	(3,059.59)	(1,672.15)	(984.56)	(10,888.74)	(7,151.77)	(8,391.15)	(8,384.07)	(73,682.74)	328.67
	Net income	(20)	(24)	(20)	(22)	(25)	(16)	(19)	(19)	(167)	9
	Depreciation	0	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	6,932.50	491.88	111.64	56.85	0.50	0.34	0.27	0.27	0.15	0.34
	Earnings	(24,937.58)	(15,052.41)	(1,870.31)	(558.47)	(52.47)	(24.00)	(22.75)	(22.50)	(107.25)	0.83
	Cash flow	(19,766.25)	(14,887.50)	(2,063.27)	(542.47)	(49.72)	(28.94)	(19.48)	(21.36)	(19.19)	(2.21)
	Capex	0.00	0.00	0.00	(1.43)	(0.03)	0.00	0.00	(0.02)	0.00	(0.31)
	Free cash flow	(19,766.25)	(14,887.50)	(2,063.27)	(543.91)	(49.75)	(28.94)	(19.48)	(21.37)	(19.19)	(2.52)
	Book value	6,408.75	(6,788.12)	489.73	301.41	13.31	68.50	33.85	12.71	(20.37)	(0.08)
	Shares, m	0	0	0	0	0	1	1	1	2	8
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.20
	P/S	1.80	17.15	7.09	2.51	354.10	189.92	65.68	73.37	61.01	3.27
	P/B	1.95	0.00	1.62	0.47	13.25	0.93	0.52	1.55	0.00	0.00
	EV/Sales	(2.07)	12.04	(6.73)	(7.90)	271.74	(53.75)	(105.81)	(18.76)	(33.41)	1.92
	EV/FCF	0.71	(0.39)	0.36	0.83	(2.72)	0.62	1.47	0.24	0.25	(0.30)
Cash, $m
Cash, $m	Operating cash flow	(16)	(24)	(23)	(21)	(23)	(19)	(16)	(18)	(30)	(18)
	Capex	—	—	—	0	0	—	—	0	—	(3)
	Free cash flow	(16)	(24)	(23)	(21)	(23)	(19)	(16)	(18)	(30)	(21)
Balance, $m
Balance, $m	Working capital	13	(5)	9	15	10	49	31	13	13	(3)
	Total debt	—	—	—	—	—	—	—	—	—	—
	Net debt	(21)	(4)	(17)	(23)	(19)	(55)	(39)	(21)	(21)	(4)
	Shareholders’ equity	5	(11)	5	12	6	46	28	11	(32)	(1)
Returns, %
Returns, %	ROA	(84.27)	(170.79)	(179.66)	(103.39)	(115.24)	(42.84)	(39.99)	(61.07)	(229.51)	38.59
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(246.35)	840.32	751.66	(253.56)	(283.48)	(61.81)	(50.96)	(97.22)	521.75	(42.56)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2025

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ACXP Acurx Pharmaceuticals, Inc.	$6.5M	— (loss-making)	—	—	n/m	−2.36% (below 0%: shrinking)	—	0.00%	Compare
TCRT Alaunos Therapeutics, Inc.	$6.4M	— (loss-making)	— (loss-making)	+200.00% (above 0%: growing)	n/m	+57.20% (above 0%: growing)	100.00%	0.00%	Compare
EVGN Evogene Ltd.	$6.3M	— (loss-making)	— (loss-making)	−35.02% (below 0%: shrinking)	n/m	+17.72% (above 0%: growing)	40.63%	(738.62%)	Compare
LEXX Lexaria Bioscience Corp.	$6.3M	— (loss-making)	— (loss-making)	−89.12% (below 0%: shrinking)	n/m	+53.90% (above 0%: growing)	100.00%	0.00%	Compare
ENVB Enveric Biosciences, Inc.	$6.2M	— (loss-making)	— (loss-making)	−7.28% (below 0%: shrinking)	n/m	−29.34% (below 0%: shrinking)	0.00%	0.00%	Compare
TRAW Traws Pharma, Inc.	$6.2M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−25.51% (below 0%: shrinking)	0.00%	0.00%
ALZN Alzamend Neuro, Inc.	$6.2M	— (loss-making)	—	—	n/m	+51.82% (above 0%: growing)	0.00%	0.00%	Compare
NRSN NeuroSense Therapeutics Ltd.	$6.0M	— (loss-making)	—	—	n/m	−23,458.82% (below 0%: shrinking)	—	0.00%	Compare
IMNN Imunon, Inc.	$6.0M	— (loss-making)	— (loss-making)	0.00%	n/m	−4.24% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$6.3M	—	—	−7.28%	—	+7.68%	20.32%	0.00%

All 614 Biotechnology stocks →

Traws Pharma, Inc. (TRAW) key facts

Strength: Traws Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.8 million, up 1,134.5% from fiscal 2024.
Traws Pharma, Inc. (TRAW) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, TRAW traded at $0.37, a market capitalization of $6.2 million.
Return on equity was −42.6% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −89.55 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.